During the past year, the Retroviral Diseases Section has conducted research on human immunodeficiency virus (HIV) disease. We have been focusing on two areas: the HIV protease and developing an immune response to peptide sequences that confer resistance to anti-HIV drugs. The first part of the project is exploring the feasibility of developing a novel therapy to HIV protease through inhibition of HIV protease dimerization. HIV protease is a dimer composed of two identical monomers. Our group previously found that glutathiolation of a conserved cysteine (Cys 95) at the HIV protease dimer interface abolishes HIV-1 protease activity. This suggested that the dimer interface and inhibition of dimerization could be a novel target for drug development. We showed that several peptides could be designed that interfered with HIV protease dimerization and that this peptide could block HIV viral production from infected cells. We are exploring the effect of these inhibitors on the Gag-Pol polyprotein, which needs to form a dimer and self-cleave itself to form active protease. Our hypothesis is that such dimerization inhibitors may be optimally directed at this initial dimerization of the Gag-Pol polyproteins. We are also exploring a number of small molecule inhibitors of HIV protease for their activity against Gag-Pol and against dimerization, in part in collaboration with the laboratory of Dr. Mitsuya. We have found that the protease inhibitor darunavir also has activity in inhibiting HIV protease dimerization. We have also been exploring the possibility of designing a peptide vaccine to HIV that could induce an immune response to a viral sequence that confers resistance to an HIV drug. In collaboration with Dr. Jay Berzofsky, we have engineered such an peptide that can induce a response against the M184V sequence of HIV reverse transcriptase that confers resistance to lamivudine and emtracitabine, and have initiated a clinical trial to explore this as a therapeutic vaccine. In addition, we are conducting some studies on the diagnosis and pathogenesis of HIV infection.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC006737-17
Application #
7735370
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2008
Total Cost
$618,518
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Morrow, Matthew; Valentin, Antonio; Little, Richard et al. (2008) A splenic marginal zone-like peripheral blood CD27+B220- B cell population is preferentially depleted in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 24:621-33
O'Mahony, D; Gandjbakche, Ah; Hassan, M et al. (2008) Imaging techniques for Kaposi's sarcoma. J HIV Ther 13:65-71
Davis, David A; Singer, Kathleen E; Reynolds, Irene P et al. (2007) Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells. Cancer Res 67:7003-10
Marshall, Vickie; Parks, Thomas; Bagni, Rachel et al. (2007) Conservation of virally encoded microRNAs in Kaposi sarcoma--associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease. J Infect Dis 195:645-59
Bernstein, Wendy B; Little, Richard F; Wilson, Wyndham H et al. (2006) Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy. Int J Hematol 84:3-11
Haque, Muzammel; Wang, Victoria; Davis, David A et al. (2006) Genetic organization and hypoxic activation of the Kaposi's sarcoma-associated herpesvirus ORF34-37 gene cluster. J Virol 80:7037-51
Semenova, Elena A; Johnson, Allison A; Marchand, Christophe et al. (2006) Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by alpha-hydroxytropolones. Mol Pharmacol 69:1454-60
Little, Richard F; Pluda, James M; Wyvill, Kathleen M et al. (2006) Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 107:4650-7
Davis, David A; Singer, Kathleen E; De La Luz Sierra, Maria et al. (2005) Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 105:4561-8
Yarchoan, Robert; Tosato, Giovanna; Little, Richard F (2005) Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol 2:406-15; quiz 423

Showing the most recent 10 out of 40 publications